So, here's the thing about Tilray Brands (TLRY) right now: the company is doing what you'd want a cannabis company to do—expanding into a key international growth market—but the stock is acting like it just heard some bad news. Tilray announced it's expanding its medical cannabis portfolio in Australia, adding new products under its Redecan and Good Supply brands. The idea is to give healthcare pros and patients more options, including medical cannabis flower, extracts, vapes, and pastilles.
"This initiative underscores Tilray's commitment to the Australian market, a key growth area," said Rajnish Ohri, President of International at Tilray Brands. It's a logical move, tapping into the growing global demand for medical cannabis. But the market, in its infinite wisdom, seems more focused on the big picture than this specific bit of corporate strategy.
The broader market was having a rough day, with the Materials sector down 2.18%, and Tilray's stock got caught in the downdraft. It's a classic case of a stock being moved more by the tide than by its own paddle.
What the Charts Are Saying
If you look at the technicals, the picture isn't exactly rosy. The stock is trading 11.3% below its 20-day simple moving average and a whopping 30% below its 100-day average. That's the technical analyst's way of saying the short- to medium-term trend is bearish. Over the past 12 months, shares are up a modest 1.82%, but they're currently hanging out much closer to their 52-week lows than their highs.
The Relative Strength Index (RSI) is sitting at 32.93, which is considered neutral territory—not oversold, not overbought. But the MACD indicator is at -0.3179, below its signal line at -0.2970, which suggests there's still some bearish pressure on the stock. Put them together, and you get mixed momentum signals. The market can't quite decide what to do with Tilray in the near term. For the traders watching, a key level to watch is $7.00, which acts as a resistance point the stock needs to break through.
For those who need a quick refresher, Tilray is a Canadian cannabis producer. Most of its sales come from Canada and the international medical cannabis export market. Its exposure to the U.S. market comes mainly from its alcohol business. The company today is the result of a 2021 reverse merger where the legacy Aphria company acquired the legacy Tilray and then took the Tilray name.
What the Analysts Think and What's Next
The general consensus among the folks who get paid to have opinions on stocks is to Hold Tilray. In a recent move, Roth Capital reiterated a Neutral rating but lowered its price target to $10.00 back on January 20.
Looking ahead, the company's next scheduled financial update is way out on the horizon—estimated for April 7, 2026. For that report, analysts are expecting a loss of one cent per share, which is down from an expectation of breaking even. On the brighter side, they're forecasting revenue to climb to $203.15 million, up from $185.78 million previously.
The ETF Factor
Here's an interesting quirk for Tilray investors to keep in mind: the stock isn't just traded on its own merits. It's a major component of certain exchange-traded funds (ETFs). Most notably, it makes up a hefty 15.49% of the Amplify Alternative Harvest ETF (MJ). What does that mean in practice? If a bunch of money flows into or out of that ETF, the fund managers have to automatically buy or sell Tilray stock to match that weight. So, sometimes the stock's price action can be driven more by ETF flows than by company-specific news.
Where the Stock Stands
Putting it all together, Tilray shares were down 2.01%, trading at $6.59 at the time of publication. The company is making strategic moves in a promising market, but for now, the stock is wrestling with a bearish technical setup and a generally weak market mood.
